TY  - GEN
N2  - Our ability to therapeutically manage breast tumors has been revolutionized by the use of drugs targeting the activity of the estrogen and HER2 receptors. However, the efficacy of these treatments is restricted to tumors expressing/overexpressing these receptors, leaving the 18% of patients that lack ER and HER2 receptor expression minimal options for therapy. In particular, triple negative (TN) breast cancer patients are limited to a small set of chemotherapeutics for treatment options. Many small molecule kinase inhibitors are currently under clinical investigation for treatment of TN tumors, but despite targeting pathways shown to be commonly upregulated in this subtype, clinical success with these single agent targeted therapies has been poor. In this work we attempt to better understand the resistance mechanisms underlying the innate resistance of TN tumors to targeted kinase inhibitors.
DO  - 10.6083/m479446z
DO  - DOI
AB  - Our ability to therapeutically manage breast tumors has been revolutionized by the use of drugs targeting the activity of the estrogen and HER2 receptors. However, the efficacy of these treatments is restricted to tumors expressing/overexpressing these receptors, leaving the 18% of patients that lack ER and HER2 receptor expression minimal options for therapy. In particular, triple negative (TN) breast cancer patients are limited to a small set of chemotherapeutics for treatment options. Many small molecule kinase inhibitors are currently under clinical investigation for treatment of TN tumors, but despite targeting pathways shown to be commonly upregulated in this subtype, clinical success with these single agent targeted therapies has been poor. In this work we attempt to better understand the resistance mechanisms underlying the innate resistance of TN tumors to targeted kinase inhibitors.
T1  - Measuring and managing phenotypic heterogeneity and plasticity in breast cancer to improve therapeutic control
DA  - 2017
AU  - Risom, Tyler
L1  - https://digitalcollections.ohsu.edu/record/7637/files/Risom.Tyler.2017.pdf
PB  - Oregon Health and Science University
PY  - 2017
ID  - 7637
L4  - https://digitalcollections.ohsu.edu/record/7637/files/Risom.Tyler.2017.pdf
KW  - Carcinoma
KW  - Triple Negative Breast Neoplasms
KW  - Drug Interactions
KW  - Breast
KW  - Epigenomics
TI  - Measuring and managing phenotypic heterogeneity and plasticity in breast cancer to improve therapeutic control
Y1  - 2017
L2  - https://digitalcollections.ohsu.edu/record/7637/files/Risom.Tyler.2017.pdf
LK  - https://digitalcollections.ohsu.edu/record/7637/files/Risom.Tyler.2017.pdf
UR  - https://digitalcollections.ohsu.edu/record/7637/files/Risom.Tyler.2017.pdf
ER  -